FDA Greenlights Yale-Developed Breast Cancer Therapy
In a significant stride for breast cancer treatment, the FDA has approved Vepdegestrant, a Yale-developed oral therapy targeting specific genetic mutations. This marks the first approval of its kind for a PROTAC-based drug, aimed at treating advanced breast cancer with …
Read more →
